| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $30,390,527 ) (Continued on the next page) |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA279840 | Okazaki fragment maturation: mutagenesis and cell survival | 000 | 2 | NIH | 3/14/2024 | $493,020 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | T32DK131943 | DIABETES PREVENTION / RISK / OMICS / METABOLISM / THERAPY (PROMT) INTERDISCIPLINARY TRAINING | 000 | 2 | NIH | 3/21/2024 | $151,238 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01DK134652 | Role of trefoil factor family proteins in beta cell function. | 000 | 2 | NIH | 11/9/2023 | $511,289 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA269569 | BAFF-R CAR T cell therapy for ALL | 001 | 3 | NIH | 4/25/2024 | $33,881 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA269569 | BAFF-R CAR T cell therapy for ALL | 000 | 3 | NIH | 3/15/2024 | $609,861 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01LM013876 | An integrated toolkit combining computational systems biology techniques with molecular dynamics simulations to delineate functionality of GPCRs | 000 | 3 | NIH | 3/22/2024 | $336,600 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HL156951 | Role of de novo pyrimidine biosynthesis in pathological cardiac remodeling | 000 | 3 | NIH | 1/26/2024 | $440,000 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258981 | The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | 001 | 3 | NIH | 4/18/2024 | $27,144 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258981 | The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | 000 | 3 | NIH | 12/18/2023 | $488,601 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA271497 | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | 001 | 3 | NIH | 4/17/2024 | $28,680 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA271497 | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | 000 | 3 | NIH | 2/2/2024 | $516,258 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R00CA256526 | Investigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor Microenvironments | 001 | 4 | NIH | 4/17/2024 | $24,901 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 001 | 3 | NIH | 4/17/2024 | $25,978 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R00CA256526 | Investigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor Microenvironments | 000 | 4 | NIH | 3/12/2024 | $224,099 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 000 | 3 | NIH | 11/16/2023 | $467,633 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266665 | Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer | 000 | 3 | NIH | 1/3/2024 | $649,334 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266665 | Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer | 001 | 3 | NIH | 4/16/2024 | $36,074 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 001 | 3 | NIH | 4/17/2024 | $41,021 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 000 | 3 | NIH | 11/22/2023 | $738,387 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA256989 | Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen | 000 | 3 | NIH | 3/6/2024 | $36,971 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AI151013 | KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection | 000 | 4 | NIH | 2/1/2024 | $764,036 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA244576 | Overcoming ibrutinib resistance in mantle cell lymphoma | 001 | 4 | NIH | 4/16/2024 | $22,516 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA244576 | Overcoming ibrutinib resistance in mantle cell lymphoma | 000 | 4 | NIH | 1/29/2024 | $405,279 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA254271 | Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma | 000 | 5 | NIH | 4/11/2024 | $711,759 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AG063854 | Defining the Role of Adipogenesis in Age-Associated Adiposity | 000 | 5 | NIH | 4/24/2024 | $360,800 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA249501 | Self-Management to Optimize Survivorship Care and Outcomes in Lung and Colorectal Cancer | 000 | 5 | NIH | 3/25/2024 | $707,468 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA249501 | Self-Management to Optimize Survivorship Care and Outcomes in Lung and Colorectal Cancer | 001 | 5 | NIH | 4/16/2024 | $39,305 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | K08CA245193 | Impact of the Therapeutic Alliance on Reduction of Disparities in Latino End-of-Life Cancer Care | 000 | 6 | NIH | 4/17/2024 | $237,924 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HD096152 | Mammary Adipocyte Remodeling in Health and Disease | 000 | 5 | NIH | 2/16/2024 | $333,749 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA249460 | Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers | 001 | 5 | NIH | 4/16/2024 | $39,410 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA249460 | Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers | 000 | 5 | NIH | 3/11/2024 | $709,370 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA248475 | Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target? | 001 | 5 | NIH | 4/18/2024 | $25,529 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA248475 | Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target? | 000 | 5 | NIH | 3/14/2024 | $459,519 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R25CA240111 | Interdisciplinary Communication Training in Oncology | 001 | 5 | NIH | 4/18/2024 | $90,305 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R25CA240111 | Interdisciplinary Communication Training in Oncology | 000 | 5 | NIH | 2/9/2024 | $203,109 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA240910 | Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia | 001 | 5 | NIH | 4/18/2024 | $21,183 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA240910 | Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia | 000 | 5 | NIH | 4/1/2024 | $381,301 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA247368 | Fatty acids and their receptors-mediated tumor metastasis and progression | 001 | 5 | NIH | 4/16/2024 | $20,131 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA247368 | Fatty acids and their receptors-mediated tumor metastasis and progression | 000 | 5 | NIH | 1/4/2024 | $362,340 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HL150069 | Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation | 000 | 5 | NIH | 2/2/2024 | $630,427 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA248149 | Role of Protein Arginine Methyltransferase 9 in Acute Myeloid Leukemia Maintenance | 001 | 5 | NIH | 4/18/2024 | $21,676 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA248149 | Role of Protein Arginine Methyltransferase 9 in Acute Myeloid Leukemia Maintenance | 000 | 5 | NIH | 2/19/2024 | $390,165 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA243386 | Targeting FTO to treat acute myeloid leukemia | 001 | 5 | NIH | 4/16/2024 | $28,529 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA243386 | Targeting FTO to treat acute myeloid leukemia | 000 | 5 | NIH | 11/13/2023 | $513,526 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA233664 | DNA repair gene mutations and prostate cancer | 000 | 5 | NIH | 11/29/2023 | $627,975 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA233664 | DNA repair gene mutations and prostate cancer | 001 | 5 | NIH | 4/17/2024 | $34,888 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA247550 | Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells | 001 | 5 | NIH | 4/17/2024 | $22,284 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA247550 | Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells | 000 | 5 | NIH | 11/20/2023 | $401,118 |
| 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA236500 | Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma | 001 | 6 | NIH | 4/16/2024 | $42,627 |
|